A new study of young heart attack sufferers revealed a sobering, albeit unsurprising, finding: More than 90 percent had at least one modifiable risk factor. What’s equally concerning, according to the authors, is the prevalence of most of these risk factors increased over the decade-long study.

Although octogenarians undergoing transcatheter or surgical aortic valve replacement (TAVR or SAVR) experienced similar rates of in-hospital mortality and vascular complications, a recent analysis from the National Inpatient Sample concluded patients who received the less-invasive procedure had shorter hospital stays and fared better for a range of other outcomes.

Optimizing hemodynamics for heart failure (HF) patients with continuous-flow left ventricular assist devices (LVADs) significantly reduces the rate of those patients’ hospital readmissions, according to a study published Feb. 1 in Circulation: Heart Failure.

ProvideGx, a subsidiary of Premier, will begin its offerings with metoprolol, a beta-blocker that can treat blood pressure and angina and is commonly given to heart attack patients.

Biologic treatment favorably modifies coronary plaque characteristics for patients with severe psoriasis, suggests a study published Feb. 5 in Cardiovascular Research. The findings raise the possibility that the anti-inflammatory drugs can both treat psoriasis and reduce cardiovascular risk.

The lifetime cumulative risk of sudden cardiac death (SCD) is much higher in black patients than in whites, according to an analysis of the Atherosclerosis Risk in Communities Study published in Circulation Feb. 4.

Fast-acting, inhalable insulin is growing in popularity among American adults with diabetes, local Minnesota outlet Fox 9 reported Feb. 1.

A patient’s degree of frailty could predict their functional outcomes in the year following transcatheter or surgical aortic valve repair (TAVR or SAVR), according to research out of Beth Israel Deaconess Medical Center in Boston.